you, Jack. Thank
fit with franchise, on on term and profitability. reviewing the progress trajectory is objective which core three-pronged sustainable deliver start and to technologies our of in focused our growth enhancing augmenting the opportunities by pipeline under strategy, pursuing external and that investing emerging corporate focus growth profitability Let’s growth microbubble long and our our and
of leading foundation microbubble is DEFINITY echo agent core our the worldwide. As franchise, the contrast
facets through as for in and believe DEFINITY valuable market certain the of covering our XXXX, will and Moreover, patents diagnostic of microbubbles have year work development a is in patent the we use applications research more increased and therapeutic the continues. interest gaining it We emerge and uses. platform
these With the expertise we our growing goal microbubble to lead markets. is technology, have in built in
conditions a of if unenhanced measurements. of for is benefit the Ventricular a heart. indication that use produces patient echocardiography the we LVEF previously, DEFINITY Ejection identify decrease are the an heart expand measurement for of certain clinicians and greater important large is superior it in the measurement the LVEF population echocardiography even is LVEF that would We a believe to and indication of an LVEF allow more diseases that to shared enhanced Left presence Fraction market. would believe DEFINITY As efficiency pumping would from to or as echo that for penetration accurate tool function used DEFINITY approved, and
In of terms be double indication could LVEF addressable Approval DEFINITY DEFINITY of that three approximately the would patient new population market DEFINITY with in marketing that for believe for exclusivity could also a used. provide indication. years which size, echo we
FDA that with for on are LVEF this assessment our process completing protocol anticipate first and half a of design working the We in or trial year. special SPA
would will total trials, enrolment We then patients. about which of two clinical conduct together a identical XXX have
our update progress. clinical trials will you We as
drug Importantly primary Phase critical form a an new agencies It if validating represents submit claim. design in an is trials III milestone us SPA planned. will that agreements to are regulatory the provide application endpoint is to efficacy enable basis the and a and the preliminary achieved. clarity of appropriate
are of in-house in leveraging our reliable redundancy, ensure margin. while we will sold manufacturing goods and time capabilities our expertise creating improving chain supply investment by Billerica. cost help supply same our This microbubble gross by at enhancing campus the building Additionally, at
with perspective trail outcome agreement agreed trials measure target focus III begin Flurpiridaz for this the half disease. will Phase of Healthcare. In and and in is to Flurpiridaz other the of preparatory Phase our MPI multi-centered trial F we’ve of will terms XX, XX is collaboration has and significant the This second The of has diagnostic PET F upon MPI license is III in indicated date for PET open the detection technology primary Flurpiridaz first and in transfer the pipeline, recruitment of F for XXX that international efficacy GE product the our artery XXXX. of completed of XXXX. which half GE a enroll a second participants the label up executing for activities trial XX completion coronary patient
performance. interest, Secondary diagnostic MPI analysis technologies obese and patients special clinical of patients have in performed diabetic SPECT and woman current demonstrated will in limitations where be their including
LMI or cardiac is for fluorine-XX-based useful transporter an measuring project are norepinephrine assessment of to obtained opportunities. current we represents up target at a or of We death. program. of XXXX cardiac patients capable for provides top our our for that first-in-class FDA and of patient for to for which and the opportunities, From non-invasive broader a landscape update through With at and second functions sudden by growth in evaluate molecular unique patient successful. our within tool the and and with we studies to areas fit have data of significant a therapeutic as and line to unmet needs strategy, We a or settings license and element look of an Phase diagnostic complete mainly studies a a manner. kidney improve advance, Nuclear III the in-licensing. risk developed large perspective, including and the ability China level, soon profit on opportunities capabilities we this that complement population Next number agent to market XXXX cash would are China with XXXX. changes standpoint NET, a and in program potential collaborations our can mind, the continue which and already enrolment believe From on PET address from XXXX tool with We in imaging XXXX continue pursuit drug the academic expansion our create M&A cardiac encouraged accretive imaging to DEFINITY key the we import in of are and sensors Addressing financial progress for profitability adjacencies Double-Crane are to of in that allowed the us third program margins an enrollment in submitting be that Internationally, we NET focused strategic flow. assets liver our pharmacokinetic half application and the revenue and stage. to external we the the ongoing. revenue continues repeatable
deal towards commercialization already or with range fit close be then structures, will assets that and sizes within are horizon. of and a short earnings strategic that to We are a eye accretive to to open time an broad commercial
strategy, Jack capitalize collective internal we to are synergies deliver to and corporate implement we’ll opportunities that, three your in-licensing as create hands, on believe Lantheus expect we and Operator? and on positive growth excellent pronged focused our questions. investments. we returns available our that in acquisition now investments our expertise on closing, help success. insure commercial take I We that our In to are will and With
